GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Current Deferred Revenue

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Current Deferred Revenue : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Clarity Pharmaceuticals's current deferred revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Clarity Pharmaceuticals Current Deferred Revenue Historical Data

The historical data trend for Clarity Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Current Deferred Revenue Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Current Deferred Revenue
- -

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Clarity Pharmaceuticals Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.